Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M479Revenue (TTM) $M121Net Margin (%)-34.7Altman Z-Score1.7
Enterprise Value $M366EPS (TTM) $-1.0Operating Margin %-35.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)-34.7Higher ROA y-yN
Price/Book3.910-y EBITDA Growth Rate %--Quick Ratio2.9Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %--Current Ratio3.0Lower Leverage y-yN
Price/Free Cash Flow89.6y-y EBITDA Growth Rate %-162.0ROA % (ttm)-19.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-29.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M43.2ROIC % (ttm)-945.5Gross Margin Increase y-yN

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2016-03-31 Reduce$7.23 - $9.31
($8.23)
$ 11.1135%Reduce -0.49%3,927,000
VNDAJohn Paulson 2015-06-30 Reduce$9.09 - $13.42
($10.76)
$ 11.113%Reduce -0.09%3,946,500
VNDAJohn Paulson 2015-03-31 Add0.02%$8.99 - $14.58
($11.3)
$ 11.11-2%Add 8.97%3,950,000
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 11.11-16%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 11.11-21%New holding1,392,500
VNDAFirst Eagle Investment 2013-09-30 Sold Out -0.024%$8.05 - $13.03
($10.66)
$ 11.114%Sold Out0
VNDAFirst Eagle Investment 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 11.1165%Reduce -48.99%975,000
VNDAFirst Eagle Investment 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 11.11214%Add 43.16%1,911,452
VNDAFirst Eagle Investment 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 11.112%Add 111.12%752,375
VNDAFirst Eagle Investment 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 11.113%New holding356,375
VNDAFirst Eagle Investment 2009-06-30 Sold Out $0.9 - $14.64
($7.49)
$ 11.1148%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.9624view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.9624view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.9624view
Flynn James E 2015-12-16Buy11,170$8.9723.86view
Flynn James E 2015-12-11Buy1,201,364$8.3832.58view
Flynn James E 2015-12-11Buy425,982$8.629.19view
Polymeropoulos Mihael HristosPresident and CEO 2015-09-10Sell131,739$12.68-12.38view
Polymeropoulos Mihael HristosPresident and CEO 2015-05-22Sell186,395$10.367.24view
Polymeropoulos Mihael HristosPresident and CEO 2015-03-10Sell21,900$10.535.51view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2015-03-10Sell12,450$10.535.51view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 24 2016
Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference Jun 20 2016
Vanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference Jun 20 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 16 2016
FDA gives Vanda Pharmaceuticals three-year marketing exclusivity for Fanapt Jun 15 2016
Here’s Why Traders Are Buzzing about These Five Stocks Jun 15 2016
FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to... Jun 15 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 15 2016
FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to... Jun 15 2016
How one investor is staying with Vanda Jun 14 2016
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference Jun 03 2016
Vanda Pharmaceuticals Inc. (VNDA)’s Stock Jumps Following NDA Approval May 27 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 26 2016
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance... May 26 2016
Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance... May 26 2016
ETF’s with exposure to Vanda Pharmaceuticals, Inc. : May 16, 2016 May 16 2016
VANDA PHARMACEUTICALS INC. Financials May 13 2016
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May... May 13 2016
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement May 12 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)